SCHEMBL2280674

SCHEMBL2280674

COC(=O)/C=C/c1cccc(C=O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.58
APP P05067 1/20 0.58
PTPN1 P18031 1/20 0.55
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
TYR P14679 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA14 Q9ULX7 1/20 0.54
EPHX2 P34913 1/20 0.54
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
JAK2 O60674 1/20 0.53
GAA P10253 1/20 0.53
HTT P42858 1/20 0.53
SIRT2 Q8IXJ6 1/20 0.52
SIRT1 Q96EB6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280675 1.00 TTR (0.58) TTRAPPPTPN1CA12CA1
SCHEMBL69618 0.93 TTR (0.66) TTRAPPPTPN1CA12CA1
3-Formylbenzoic Acid SCHEMBL4423601 0.88 UNG (0.66) TTRAPPPTPN1CA12CA1
3-Formylbenzoic Acid SCHEMBL4423592 0.88 UNG (0.66) TTRAPPPTPN1CA12CA1
SCHEMBL4423599 0.87 P4HB (0.53) TTRAPPPTPN1CA12CA1
E-Methyl Cinnamate SCHEMBL5487325 0.84 KMT2A (0.68) TTRAPPPTPN1CA12CA1
SCHEMBL30676338 0.84 CA12 (0.66) TTRAPPPTPN1CA12CA1
E-Methyl Cinnamate SCHEMBL5487323 0.84 KMT2A (0.68) TTRAPPPTPN1CA12CA1
SCHEMBL2631340 0.84 CA12 (0.66) TTRAPPPTPN1CA12CA1
SCHEMBL3065424 0.84 CA12 (0.66) TTRAPPPTPN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Liminal Biosciences Limited (GB) 2021-11-30 US disclosed
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION LIMINAL BIOSCIENCES LTD (GB) 2021-03-25 US disclosed
US-10869849-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration Liminal Biosciences Limited (GB) 2020-12-22 US disclosed
US-20200237693-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS LIMINAL BIOSCIENCES INC (GB) 2020-07-30 US disclosed
US-10391073-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration PROMETIC PHARMA SMT LIMITED (GB) 2019-08-27 US disclosed
US-10188627-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof MITOBRIDGE, INC. (US) 2019-01-29 US disclosed
US-20170312237-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION Liminal Biosciences Limited (GB) 2017-11-02 US disclosed
US-20170312237-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION Liminal Biosciences Limited (GB) 2017-11-02 US disclosed
US-20170304255-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2017-10-26 US disclosed
WO-2016074068-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION PROMETIC BIOSCIENCES INC. (CA) 2016-05-19 WO disclosed
US-7169801-B2 Histone deacetylase inhibitors TAKEDA SAN DIEGO, INC. (US) 2007-01-30 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed
EP-1608628-A2 HISTONE DEACETYLASE INHIBITORS Takeda San Diego, Inc. (US) 2005-12-28 EP disclosed
US-20050137232-A1 Histone deacetylase inhibitors SYRRX, INC. 2005-06-23 US disclosed
US-20040266769-A1 Histone deacetylase inhibitors SYRRX, INC. 2004-12-30 US disclosed
US-20040254220-A1 Histone deacetylase inhibitors SYRRX, INC. 2004-12-16 US disclosed
WO-2004082638-A2 HISTONE DEACETYLASE INHIBITORS SYRRX, INC. (US) 2004-09-30 WO disclosed
US-5756527-A ANTICARCINOGENIC AGENTS ONTOGEN CORPORATION (US) 1998-05-26 US disclosed
EP-0812830-A1 Modulators of multi-drug resistances ONTOGEN CORPORATION (US) 1997-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION COL1A1, CCNH, COL2A1 TTR 1018/4885APP 851/4885PTPN1 2852/4885
US-20050137232-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC10 TTR 4843/4885APP 4496/4885PTPN1 4273/4885
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 TTR 3910/4885APP 3864/4885PTPN1 3840/4885
US-20170312237-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION CCNH, COL1A1, COL2A1 TTR 924/4885APP 962/4885PTPN1 2653/4885
US-20200237693-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS ADIPOR1, ADIPOR2, FN1 TTR 825/4885APP 297/4885PTPN1 1012/4885
US-10391073-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration CCNH, COL1A1, COL2A1 TTR 924/4885APP 962/4885PTPN1 2653/4885
US-20040266769-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC10 TTR 4843/4885APP 4496/4885PTPN1 4273/4885
US-10188627-B2 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof PPARG, PPARD, PPARA TTR 910/4885APP 1435/4885PTPN1 3465/4885
US-10869849-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration COL1A1, CCNH, COL2A1 TTR 1018/4885APP 851/4885PTPN1 2852/4885
US-20170304255-A1 PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF PPARG, PPARD, PPARA TTR 910/4885APP 1435/4885PTPN1 3465/4885
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis ADIPOR1, ADIPOR2, FN1 TTR 825/4885APP 297/4885PTPN1 1012/4885
US-20040254220-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC10 TTR 4843/4885APP 4496/4885PTPN1 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.